Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

Analyst Ratings

Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Show:
DateFirmActionRatingPrice TargetActions
5/6/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015Roth CapitalDowngradeBuy -> Sell$5.50 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015WedbushReiterated RatingHold$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2015BTIG ResearchInitiated CoverageBuy$5.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$9.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/29/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q116($0.12)($0.12)$0.77 million$0.64 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.14)($0.15)$0.84 million$0.67 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.12)($0.09)$1.09 million$0.68 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215($0.13)($0.15)$1.21 million$0.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.16)($0.13)$1.14 million$0.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.20)($0.02)$1.17 million$0.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.17)($0.25)$1.97 million$0.85 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214($0.17)($0.20)$1.32 million$2.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.17)($0.26)$1.32 million$2.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012($0.20)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2012($0.18)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2011($0.18)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2011($0.15)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/26/2016Geoffrey M ParkerDirectorBuy9,500$0.47$4,465.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Geoffrey M ParkerDirectorBuy52,505$0.47$24,677.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Dayton MisfeldtDirectorBuy1,750,000$0.84$1,470,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Daniel N Swisher JrCEOBuy12,216$1.01$12,338.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Daniel N Swisher JrCEOBuy12,784$1.01$12,911.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Forest BaskettMajor ShareholderSell266,700$7.97$2,125,599.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Bay City Capital LlcMajor ShareholderSell300,700$7.98$2,399,586.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Dayton MisfeldtDirectorSell200,000$7.89$1,578,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Adam R CraigCMOSell2,554$8.00$20,432.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Daniel N Swisher JrCEOSell5,000$8.00$40,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Dayton MisfeldtDirectorSell100,700$8.16$821,712.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Eric BjerkholtCFOSell10,000$8.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Krishna Kittu KolluriMajor ShareholderSell108,300$8.17$884,811.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Dayton MisfeldtDirectorSell743,700$6.64$4,938,168.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Equity Opportunities Fu GrowthMajor ShareholderSell710,540$6.63$4,710,880.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
DateHeadline
07/22/16 09:24 AMStock Moving Lower for the Month; Investor Update on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Engelwood Daily
07/22/16 09:24 AMSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 09:24 AMIs $2.5 Price Target Attainable For Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)? - Investor Newswire
07/22/16 09:24 AMEquity Roundup: Stock Performance Focus on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Press Telegraph
07/22/16 09:24 AMSunesis Pharmaceuticals Inc (NASDAQ:SNSS) Stock Technicals at Critical Inflection Point - CML News
07/21/16 09:19 AMInsiders Increasing Positions in: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Press Telegraph
07/21/16 06:00 AMSunesis to Host Conference Call on July 29th to Discuss Second Quarter 2016 Financial Results and Recent Highlights - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., July 21, 2016-- Sunesis Pharmaceuticals, Inc. today announced that it will host a conference call on Friday, July 29, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates ...
07/18/16 11:40 AMOption Market: Sunesis Pharmaceuticals Inc Risk Hits An Extreme High - CML News
07/17/16 10:31 AMShares Moving Down on the Week: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Engelwood Daily
07/15/16 05:28 PMStrong Sell Calls For Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) At 0 - Investor Newswire
07/14/16 10:07 AMTrading Performance and Target Watch for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Press Telegraph
07/13/16 06:54 PMSunesis Pharmaceuticals, Inc. Forms Double Bottom; Strong Momentum for Sellers - Consumer Eagle
07/13/16 09:23 AMSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 10:52 AMSunesis Pharmaceuticals, Inc. (SNSS) Updated Price Targets - FTSE News
07/09/16 05:49 PMHow Many Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)'s Analysts Are Bullish? - Engelwood Daily
07/09/16 05:49 PMBrokers Issue Average Price Target Of 2.12 On Sunesis Pharmaceuticals, Inc. (SNSS) - Fiscal Standard
07/09/16 05:49 PMSunesis Pharmaceuticals Inc. Realized Volatility Hits Extreme Level - CML News
07/08/16 06:28 PMCan Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Improve on the Earnings Front? - Engelwood Daily
07/08/16 09:21 AMCompany Stock Focus for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): Which Way Will Shares Head? - Press Telegraph
07/08/16 09:21 AMIs $2.5 Within Reach For Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)? - Investor Newswire
07/07/16 06:34 PMSunesis Pharmaceuticals (SNSS) : Analyst Rating Update - TheFounders Daily
07/05/16 06:09 PMSunesis Pharmaceuticals, Inc. (SNSS) Broker Price Targets For The Coming Week - Fiscal Standard
07/05/16 07:01 AMSunesis Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at Cantor ...
07/02/16 09:06 AMHow Many Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)'s Analysts Are Bearish? - Press Telegraph
06/30/16 06:43 PMSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Expected to Reach Highs Of $2.5 - Investor Newswire
06/29/16 09:14 AMSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Company Rating and Target Watch - Telanagana Press
06/27/16 10:35 AMShare Update and Earnings Review for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Press Telegraph
06/26/16 10:50 AMHow Analysts Feel About Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)? - Engelwood Daily
06/24/16 09:02 AMSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 09:02 AMCovering the Bases on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): Where is the Stock Going? - Press Telegraph
06/24/16 09:02 AMStrong Sell Calls Recommendations For Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) At 0 - Investor Newswire
06/24/16 09:02 AMSunesis Pharmaceuticals, Inc. (SNSS) Current Analyst Ratings - Fiscal Standard
06/22/16 06:26 PMSunesis Pharmaceuticals: Qinprezo/Dacogen Combo Stands Up
06/22/16 11:07 AMSunesis Pharmaceuticals Inc. (SNSS) Jumps 8.73% on June 20 - Equities.com
06/21/16 10:47 AMBiotech Unusual Volume: Epizyme, Inc. (NASDAQ:EPZM), Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Concert ... - KC Register
06/21/16 07:45 AMSunesis Pharmaceuticals (SNSS) in Focus: Stock Gains 8.7% -
06/16/16 06:42 PMStrong Buy Calls Count For Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) At 1 - Investor Newswire
06/14/16 06:08 PMCompany Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces Presentation of Positive Clinical ... - Smarter Analyst
06/13/16 09:28 AMSunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial
06/13/16 06:59 AMSunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial in Frontline Elderly AML and MDS at the EHA Annual Meeting - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD ...
06/11/16 09:25 AMSunesis Pharmaceuticals Inc. (SNSS) Drops 5.87% on June 09 - Equities.com
06/09/16 08:42 AMMost Popular Healthcare Penny Stocks Among Hedge Funds -
06/08/16 03:14 PMSUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/08/16 09:34 AMSunesis Pharmaceuticals Inc. (SNSS) is Trading Lower on Unusual Volume for June 06 - Equities.com
06/06/16 04:43 PMETF’s with exposure to Sunesis Pharmaceuticals, Inc. : June 6, 2016 -
06/06/16 09:08 AMSunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced the presentation of results from a study conducted by the Center for International ...
06/04/16 06:35 PMAnalyst Recommended These Stocks to Buy: TiVo Inc. (NASDAQ:TIVO), Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Beacon Chronicle
06/04/16 09:29 AMSunesis Pharmaceuticals Inc. (SNSS) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/03/16 09:29 AMNew VP Could Help Save Shareholders In Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Scibility Media
06/02/16 06:58 PMBuy, Sell Or Hold Rating For Sunesis Pharmaceuticals, Inc. (SNSS)? - Share Trading News - Buy, Sell Or Hold Rating For Sunesis Pharmaceuticals, Inc. (SNSS)?Share Trading News07/24/2015 – Sunesis Pharmaceuticals, Inc. was downgraded to “sell” by analysts at Roth Capital. They now have a USD 1 price target on the stock. 07/24/2015 – Sunesis Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at Cowen.Insiders Are Gradually Buying Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)HNNall 2 news articles »

Social

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals logoSunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SNSS
  • CUSIP: 86732860
Key Metrics:
  • Previous Close: $0.50
  • 50 Day Moving Average: $0.5397
  • 200 Day Moving Average: $0.6094
  • P/E Ratio: N/A
  • P/E Growth: -0.0100
  • Market Cap: $43.48M
  • Beta: 1.88
  • Current Year EPS Consensus Estimate: $-0.4 EPS
  • Next Year EPS Consensus Estimate: $-0.53 EPS
Additional Links:
Sunesis Pharmaceuticals (NASDAQ:SNSS) Chart for Monday, July, 25, 2016